company background image
509079 logo

Gufic Biosciences BSE:509079 Stock Report

Last Price

₹449.10

Market Cap

₹45.0b

7D

5.4%

1Y

29.8%

Updated

31 Jan, 2025

Data

Company Financials

Gufic Biosciences Limited

BSE:509079 Stock Report

Market Cap: ₹45.0b

509079 Stock Overview

Manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. More details

509079 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 23.5% per year over the past 5 years

Risk Analysis

Has a high level of debt


My Notes

Capture your thoughts, links and company narrative

Gufic Biosciences Limited Competitors

Hikal

BSE:524735

₹43.8b

Aarti Drugs

BSE:524348

₹37.3b

Jeena Sikho Lifecare

NSEI:JSLL

₹45.4b

Morepen Laboratories

BSE:500288

₹35.6b

Price History & Performance

Summary of share price highs, lows and changes for Gufic Biosciences
Historical stock prices
Current Share Price₹449.10
52 Week High₹501.10
52 Week Low₹278.00
Beta0.89
1 Month Change-1.81%
3 Month Change1.83%
1 Year Change29.80%
3 Year Change89.25%
5 Year Change516.47%
Change since IPO2,679.09%

Recent News & Updates

Recent updates

Shareholder Returns

509079IN PharmaceuticalsIN Market
7D5.4%-4.0%-1.8%
1Y29.8%20.3%6.2%

Return vs Industry: 509079 exceeded the Indian Pharmaceuticals industry which returned 20.3% over the past year.

Return vs Market: 509079 exceeded the Indian Market which returned 6.2% over the past year.

Price Volatility

Is 509079's price volatile compared to industry and market?
509079 volatility
509079 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.3%

Stable Share Price: 509079 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 509079's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19701,491Pranav Choksiwww.gufic.com

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments.

Gufic Biosciences Limited Fundamentals Summary

How do Gufic Biosciences's earnings and revenue compare to its market cap?
509079 fundamental statistics
Market cap₹45.03b
Earnings (TTM)₹849.28m
Revenue (TTM)₹8.04b

53.0x

P/E Ratio

5.6x

P/S Ratio

Is 509079 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
509079 income statement (TTM)
Revenue₹8.04b
Cost of Revenue₹3.84b
Gross Profit₹4.20b
Other Expenses₹3.35b
Earnings₹849.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)8.47
Gross Margin52.28%
Net Profit Margin10.57%
Debt/Equity Ratio49.4%

How did 509079 perform over the long term?

See historical performance and comparison

Dividends

0.02%

Current Dividend Yield

1%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 20:27
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gufic Biosciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research
Naveed MD.FirstCall Research